With a 4.56% annual dividend yield, GlaxoSmithKline (NYSE:GSK) is widely held by many dividend oriented investors. GSK is actually coming off an excellent Q1 2017, which showed a 5% year-over-year increase in sales assuming constant exchange rates. With that being said, I believe GSK is a particularly risky bet for the following 3 reasons:
